Prevalence and antimicrobial-resistance of Pseudomonas aeruginosa in swimming pools and hot tubs.

International Journal of Environmental Research and Public Health
Jonathan K Lutz, Jiyoung Lee

Abstract

Pseudomonas aeruginosa is an important opportunistic pathogen in recreational waters and the primary cause of hot tub folliculitis and otitis externa. The aim of this surveillance study was to determine the background prevalence and antimicrobial resistance profile of P. aeruginosa in swimming pools and hot tubs. A convenience sample of 108 samples was obtained from three hot tubs and eight indoor swimming pools. Water and swab samples were processed using membrane filtration, followed by confirmation with polymerase chain reaction. Twenty-three samples (21%) were positive for P. aeruginosa, and 23 isolates underwent susceptibility testing using the microdilution method. Resistance was noted to several antibiotic agents, including amikacin (intermediate), aztreonam, ceftriaxone, gentamicin, imipenem, meropenem (intermediate), ticarcillin/clavulanic acid, tobramycin (intermediate), and trimethoprim/sulfamethoxazole. The results of this surveillance study indicate that 96% of P. aeruginosa isolates tested from swimming pools and hot tubs were multidrug resistant. These results may have important implications for cystic fibrosis patients and other immune-suppressed individuals, for whom infection with multidrug-resistant P. aerugi...Continue Reading

References

Sep 1, 1988·Journal of Clinical Microbiology·D Price, D G Ahearn
Mar 1, 1988·Applied and Environmental Microbiology·M W LeChevallierR G Lee
Jan 1, 1985·Applied and Environmental Microbiology·D J Reasoner, E E Geldreich
Mar 1, 1983·Reviews of Infectious Diseases·G P BodeyL Jadeja
Sep 1, 1984·Reviews of Infectious Diseases·A J Morrison, R P Wenzel
Jul 1, 1984·Applied and Environmental Microbiology·G E MurrayD J Kushner
Oct 1, 1995·Genitourinary Medicine·D Moore, M Nelson
May 21, 1999·Archives of Internal Medicine·Y CarmeliM H Samore
May 16, 2000·International Journal of Dermatology·L ZichichiG Noto
Nov 30, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Y F BerrouaneL A Herwaldt
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C GalesR Ramphal
Jan 26, 2002·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·K KatoUNKNOWN Tokyo Johoku Association of Pseudomonas Studies
Oct 24, 2002·Critical Care Medicine·Stefan ReuterMatthias Trautmann
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Valerie AloushYehuda Carmeli
Jun 6, 2006·The American Journal of Medicine·Leanne B GasinkEbbing Lautenbach
Mar 20, 2009·Journal of Clinical Microbiology·Lori M DulabonMichael Cynamon
Jun 17, 2009·Journal of Medical Microbiology·Tanya Strateva, Daniel Yordanov
Jan 1, 2006·Environmental Health and Preventive Medicine·Naomi Sakurai-KomadaKazuko A Koike

❮ Previous
Next ❯

Citations

Jun 26, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Sep 24, 2013·Medicina clínica·Miquel AlsedàM Àngels Borràs
Aug 19, 2015·Journal of Applied Microbiology·D O SantoroM M Clementino
May 23, 2012·International Journal of Hygiene and Environmental Health·Arnau Casanovas-Massana, Anicet R Blanch
May 18, 2012·Dermatologic Therapy·Susan Y ChonStephen K Tyring
Oct 19, 2016·American Journal of Industrial Medicine·Thibaud SoumagneJean Charles Dalphin
Nov 9, 2016·Annales de dermatologie et de vénéréologie·N SokolowskyM Beylot-Barry
Feb 5, 2015·Revista Do Instituto De Medicina Tropical De São Paulo·Vinicius José MaschioMarilise Brittes Rott
Dec 19, 2013·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Jessica MillerKathleen M Gura
Jun 21, 2017·International Journal of Environmental Health Research·Karmen Godič Torkar, Mirjana Dražetić
Mar 21, 2019·Expert Review of Respiratory Medicine·Nicola J RowbothamAlan R Smyth
Oct 31, 2018·Journal of the American Animal Hospital Association·Jason W StullHeather L Troyer
Dec 17, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·I M Balfour-Lynn
Feb 4, 2021·Praxis·Gioia Braun-MeyreHamid Khani
Dec 18, 2020·Journal of Water and Health·Daisuke SanoAna Maria de Roda Husman
Dec 30, 2020·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Eleanor OsborneLucy Ostlere
Mar 18, 2021·Molecular Biology Reports·Siew Mun LiewKek Heng Chua
Dec 12, 2018·Médecine et maladies infectieuses·O PassouantJ Cousson

❮ Previous
Next ❯

Methods Mentioned

BETA
membrane filtration
PCR

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.